share_log

Zymeworks Highlights Early Data From Zanidatamab Zovodotin Trial In HER2-Positive Tumors

Zymeworks Highlights Early Data From Zanidatamab Zovodotin Trial In HER2-Positive Tumors

Zymeworks重点介绍Zanidatamab Zovodotin在HER2阳性肿瘤中的早期试验数据
Benzinga Real-time News ·  2022/09/13 09:34
  • Zymeworks Inc (NASDAQ:ZYME) presented preliminary results from its Phase 1 trial evaluating zanidatamab zovodotin (ZW49) for HER2-positive tumors.
  • The data were presented at the European Society for Medical Oncology Annual Congress.
  • A total of 77 patients were enrolled in this first-in-human trial, designed to determine the maximum tolerated dose of zanidatamab zovodotin, characterize its safety and tolerability, and evaluate anti-tumor activity in HER2-expressing cancers as monotherapy.
  • Also Read: Zymeworks Turns Down All Blue's Hostile Bid.
  • At the time of the analysis, the maximum tolerated dose had not yet been reached.
  • In the trial, zanidatamab zovodotin was shown to have a manageable safety profile, with the majority of adverse events being mild or moderate.
  • In patients with HER2-positive cancers treated with zanidatamab zovodotin at 2.5 mg/kg Q3W, the confirmed objective response rate was 31%, and the disease control rate was 72%.
  • The Phase 1 trial continues to enroll patients to study safety. The company expects to present the results of this dosing regimen at a medical meeting in 2023.
  • Price Action: ZYME shares are up 0.20% at $4.95 during the market session on the last check Tuesday.
  • Zymeworks Inc.纳斯达克公司(JYME)公布了评估zanidatamab zovodotin(ZW49)治疗HER2阳性肿瘤的第一阶段试验的初步结果。
  • 这些数据是在欧洲医学肿瘤学学会年会上公布的。
  • 共有77名患者参加了这项首次人体试验，旨在确定zanidatamab zovodotin的最大耐受量，表征其安全性和耐受性，并评估HER2表达的癌症作为单一疗法的抗肿瘤活性。
  • 另请阅读： Zymeworks拒绝了All Blue的敌意收购.
  • 在进行分析时，尚未达到最大耐受量。
  • 在试验中，zanidatamab zovodotin被证明具有可控的安全性，大多数不良事件为轻度或中度。
  • 在HER2阳性癌症患者中，Zanidatamab Zovodotin 2.5 mg/kg q3w治疗后，确认的客观缓解率为31%，疾病控制率为72%。
  • 1期试验继续招募患者进行安全性研究。该公司预计将在2023年的一次医学会议上公布这种剂量方案的结果。
  • 价格行动：在周二尾盘交易中，ZYME股价上涨0.20%，至4.95美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发